GB9104806D0 - Method for preventing onset of or treating protein catabolism - Google Patents

Method for preventing onset of or treating protein catabolism

Info

Publication number
GB9104806D0
GB9104806D0 GB9104806A GB9104806A GB9104806D0 GB 9104806 D0 GB9104806 D0 GB 9104806D0 GB 9104806 A GB9104806 A GB 9104806A GB 9104806 A GB9104806 A GB 9104806A GB 9104806 D0 GB9104806 D0 GB 9104806D0
Authority
GB
United Kingdom
Prior art keywords
protein catabolism
treating protein
preventing onset
preventing
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9104806A
Other versions
GB2241890A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of GB9104806D0 publication Critical patent/GB9104806D0/en
Publication of GB2241890A publication Critical patent/GB2241890A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is provided for preventing onset of or treating protein catabolism in hypertensive or normotensive patients and thereby preventing loss of muscle mass in such patients by administering an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril, as well as fosinopril.
GB9104806A 1990-03-12 1991-03-07 Preventing onset of or treating protein catabolism using an ace inhibitor Withdrawn GB2241890A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49204690A 1990-03-12 1990-03-12

Publications (2)

Publication Number Publication Date
GB9104806D0 true GB9104806D0 (en) 1991-04-17
GB2241890A GB2241890A (en) 1991-09-18

Family

ID=23954719

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9104806A Withdrawn GB2241890A (en) 1990-03-12 1991-03-07 Preventing onset of or treating protein catabolism using an ace inhibitor

Country Status (1)

Country Link
GB (1) GB2241890A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2183128C2 (en) 1996-07-15 2002-06-10 Санкио Компани Лимитед Pharmaceutical composition
CA2677910C (en) 1997-10-17 2011-03-15 Ark Therapeutics Limited The use of inhibitors of the renin-angiotensin system for the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
GB2241890A (en) 1991-09-18

Similar Documents

Publication Publication Date Title
ZA945249B (en) Parathyrold hormone and raloxifene for increasing bone mass
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
GR3021087T3 (en) Compositions for treating ischemia-related neuronal damage.
HU896344D0 (en) Method for the treatment of leather by applying amphilyl copolymers
MX9805810A (en) Anticoagulant agents useful in treatment of thrombosis.
HU9202072D0 (en) An improved method for treatment of autoimmunic diseases by means of introduction of autoantigenes in form of aerosol
PL320484A1 (en) Method of treating diabetes using kgf
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
IE831631L (en) Composition for the treatment of wounds.
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
MY115046A (en) Medicinal composition for diabetes
GB9104806D0 (en) Method for preventing onset of or treating protein catabolism
EP0321221A3 (en) Method for preventing or treating anxiety employing an ace inhibitor
ATE251462T1 (en) METHOD FOR TREATING SCAR TISSUE
NO982582L (en) Procedure for the treatment of pain
EP0431784A3 (en) Methods for treating retroviral infection
GB8812533D0 (en) Instrument for surgical treatment of pieces of tissue
GB2331460A (en) Pharmaceutical composition for the treatment of hepatitis B comprising extract of phyllanthus ussuriensis and/or phyllanthus urinaria
YU25789A (en) Process for hide treating
MX9701332A (en) Methods for bone healing and fracture repair.
PL328924A1 (en) Method of treating abuse of substances
PL328949A1 (en) Method of treatng excessive aggression
BG47878A1 (en) Method for thermochemical treatment of azotic austenitic steels
IL107015A0 (en) Method for treatment of blood

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)